What Baxter's FY2025 10-K says: 12 signals
Baxter filed its latest 10-K with the SEC on Feb 12, 2026. It discusses automation investment, bookings decline and capex increase.
Public (BAX)Medical Equipment Manufacturing10,000+ employeesbaxter.comLinkedIn
- Filed
- Feb 12, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 10
What Baxter's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Class I recalls on Novum LVP infusion pumps led to a distribution halt and $105M in charges in 2025.
Multiple voluntary corrections for the Novum LVP, classified as Class I recalls by the FDA due to infusion risks, forced a distribution and installation stop in the U.S.
$105M
Aggregate charges in 2025 for sales reductions, returns, remediation, and write-downs for Novum LVP corrections.
Invested $513M in CapEx during 2025 to improve production and quality systems
The company is making significant capital investments to improve production efficiency, enhance quality systems, and optimize manufacturing capabilities.
$513M
Total capital expenditures in 2025.
Paid down $3.81B in debt in 2025, targeting 3.0x net leverage by end of 2026
Baxter is aggressively deleveraging its balance sheet following the sale of its Kidney Care business, paying down $3.81B in debt.
$3.8B
Legacy indebtedness paid down in 2025.
A hurricane damaged the North Cove, N.C. facility, disrupting operations and supply.
Rising inflation in shipping, labor, and other costs is directly impacting profitability because long-term customer contracts and GPO pricing agreements limit the company's ability to raise prices.
Baxter divests Kidney Care and BPS businesses to focus portfolio and reduce debt
The company has completed the sale of its Kidney Care and BioPharma Solutions (BPS) businesses, using proceeds to pay down $3.81 billion in debt in 2025.
$3.8B
legacy indebtedness paid down in 2025
Relies on Cardinal Health and Medline for a significant portion of US distribution
Baxter uses third-party distributors Cardinal Health and Medline to warehouse and ship a significant portion of its products in the US.
Cardinal Health, Inc.Medline Inc.
Baxter invests $513M in CapEx to enhance quality systems and manufacturing efficiency
Baxter is dedicating significant capital to 'improve production efficiency, enhance our quality systems and optimize manufacturing capabilities'.
$513M
Capital expenditures in 2025 for production efficiency, quality systems, and manufacturing optimization
Profitability impacted by inflation and inability to pass costs to customers
High inflation is increasing shipping, labor, and other costs, but long-term customer contracts limit Baxter's ability to raise prices accordingly.
Hurricane Helene disruption led to reduced customer demand for IV solutions
Damage and operational disruption at the North Cove, NC facility from Hurricane Helene caused supply issues, prompting customers to change practices and reduce demand for Baxter's IV solutions.
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Baxter with the Signal API
One POST /v1/companies/enrich call with baxter.com returns Baxter 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"baxter.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Baxter 10-K
When did Baxter file its latest 10-K?
What does Baxter's latest 10-K say about quality issue?
Where can I find Baxter's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .